A Study of Evacetrapib and Digoxin in Healthy Participants

• Status: Completed
• Trial end date: 2013-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with the study drug evacetrapib. This study will also look at the effect of evacetrapib on the removal of digoxin from the body by the kidneys. Information about any side effects that may occur will be collected. This study will last approximately 33 days for each participant, not including screening.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Digoxin; Evacetrapib

Criteria

Inclusion Criteria:

• Overtly healthy males and females (of non-childbearing potential)

• Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)

• Normal renal function

Exclusion Criteria:

• Participants who currently smoke or use tobacco or nicotine products